





NIDA Responds to the Syndemic of Opioids, Viral Hepatitis and HIV




Wilson M. Compton, M.D., M.P.E.
Deputy Director, National Institute on Drug Abuse

Virtually **All of the U.S.** Have Increased Drug Overdoses: Estimated Age-adjusted Death Rates per 100,000 for Drug Poisoning by County.




63,362 Deaths in 2016
(42,249 from *Prescription*
***and Illicit Opioids*)**



Evolution of the Opioid Overdose Deaths:

Analgesics ➡ *Heroin* ➡ *Fentanyl*



Viral Hepatitis , HIV and Opioid Addiction are Part of a *Syndemic* of Intersecting Epidemics


Viral Hepatitis, HIV, and opioid addiction are co-occurring epidemics.

- *Shared risk factors and causes*
- *Cross-cutting benefits of treatment*

HIV (and *Hepatitis C*) Outbreak
Linked to Oxymorphone Injection
Use in Indiana, 2015


Peters et al.
The New England Journal of Medicine
2016;375:229-239

Centers for Disease Control and Prevention
MMWR
Early Release / Vol. 64
Morbidity and Mortality Weekly Report
April 24, 2015



Syndemic Conditions

Injection Drug Use Is Driving new Hepatitis C Infections



National Notifiable Diseases Surveillance System (NNDSS)

- Persons who inject drugs are the reservoir (main source) of Hepatitis C infection
- Currently ~750,000 persons who inject drugs in USA
- Surge in Hepatitis C in young persons who inject drugs (18-25 years old)
- Heroin as an initiating opioid has increased sharply


Recommendation to Prevent Hepatitis C: ***Better access to effective OUD treatments – Buprenorphine, Methadone and Naltrexone***

Combined Use of Syringe Services Programs and Medication Assisted Treatment Reduces HCV Transmission Among People Who Inject Drugs (PWID)

HCV Infectivity: HCV Remains Infectious Up to 6 Weeks on Improperly Cleaned Surfaces

Syringe Services Programs:

- Are an effective component of an integrated approach to reduce HIV/HBV/HCV in PWID
- Also offer alcohol swabs, sterile water, condoms, naloxone, testing, and referral to treatment
- Reduce overdose deaths and increase entry into treatment



Combining high access to syringe programs with MAT reduces risk of HCV infection by


74%

*How Can **NIH/NIDA** Research Help?*



NIH Opioid Research

Using Research to End the Opioid Crisis



New NIH Initiative to Address the Crisis: HEAL: Helping to End Addiction Long-term

- Collaborative, cross-cutting research
 - From basic to behavioral – and everything between
 - Innovative partnerships – across agencies, sectors, organizations – will ensure rapid progress
- **\$500M just added by Congress**
 - Adds to \$600M current funds = \$1.1B for FY18
 - Will propel HEAL
- Advances ***national priorities for pain, addiction research***

NIDA-Supported Hepatitis C Research

- NIDA: 2nd largest NIH funder— \$32.6 M (FY2016)
- Interventions for rural, at-risk women; support for women in drug court; financial literacy & vocational training for at-risk women; tailored prenatal care for pregnant women
- Rapid HCV testing in care settings
- Utilization of case managers within a coordinated care framework




OraQuick® Rapid Antibody Test
HCV

- Adaptation of HIV model of “treatment as prevention”
- Efficacy of direct acting antivirals in substance using populations


Reported *Hepatitis C Cases by County*, 2013-2014 Combined Partnership of *NIDA and Appalachian Regional Commission* (ARC)

- Targeting opioid IDU, OD, HIV and HCV
- One-year planning grants to describe:
 - problem scope
 - contributing health trends
 - Resources, obstacles
- 4 Grants Funded RFA-DA-16-015



In FY2017 broadened program to include CDC, SAMHSA and ARC

NIDA, CDC, SAMHSA, ARC: Using Research to Combat HIV and Viral Hepatitis in Rural Areas



NIDA Joining CDC on the 2018 Update to the *National HIV Behavioral Surveillance among Persons Who Inject Drugs*

22 MSAs:



Plans for 2018

- Improve recruitment of young (<30 years) PWID
- Include HCV testing in NHBS sites
- Expand recruitment outside of urban core


Elimination of Hepatitis C

NIDA and NCI are working with CDC to develop a study of the elimination of HCV in a high-risk community in Kentucky.

Work to date includes pilot funding to the University of Kentucky to develop community-based components:

- ***Syringe exchange***
- ***Drug treatment***
- ***Linkages with criminal justice (because of high-risk persons re-entering the community)***
- ***Access to medical care.***
- ***Hepatitis C testing and TREATMENT***

www.drugabuse.gov



NIDAMED